PHASE-I STUDY OF VP-16-213 (ETOPOSIDE) ADMINISTERED AS A CONTINUOUS 5-DAY INFUSION

  • 1 January 1981
    • journal article
    • research article
    • Vol. 65  (9-10) , 887-889
Abstract
Twenty-four patients with advanced maligancy received 30 courses of VP-16-213 delivered by a protracted venous infusion for a minimum of 5 days or 120 h in a phase I study to determine the maximum tolerated dose. Toxic effects included fluid overload (due to the necessary use of normal saline as the drug delivery vehicle), stomatitis and marrow suppression with leukopenia and thrombocytopenia. Except for the stomatitis, gastrointestinal effects were virtually absent. The dose-limiting toxic effect was marrow suppression observed at a dose of 60 mg/m2 per day .times. 5 days (300 mg/m2 per course). Six of 7 patients treated at this dose developed marrow suppression; 50% (3 of 6 patients) had life-threatening leukopenia associated with fever only (1 patient), sepsis (1) and septic death (1).

This publication has 0 references indexed in Scilit: